Cantor Fitzgerald Predicts KALV FY2026 Earnings

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for KalVista Pharmaceuticals in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst P. Stavropoulos anticipates that the specialty pharmaceutical company will post earnings of ($2.90) per share for the year. The consensus estimate for KalVista Pharmaceuticals' current full-year earnings is ($3.56) per share.

Several other analysts also recently issued reports on KALV. Jones Trading reaffirmed a "buy" rating and issued a $30.00 price target on shares of KalVista Pharmaceuticals in a report on Wednesday, March 26th. HC Wainwright reaffirmed a "buy" rating and issued a $20.00 price target on shares of KalVista Pharmaceuticals in a report on Friday, March 14th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $28.00 price target on shares of KalVista Pharmaceuticals in a report on Tuesday, April 8th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $24.83.

KalVista Pharmaceuticals Stock Performance

KALV stock traded down $0.13 during trading on Wednesday, reaching $12.96. 768,473 shares of the company were exchanged, compared to its average volume of 443,959. KalVista Pharmaceuticals has a 52-week low of $7.30 and a 52-week high of $15.50. The company has a market cap of $644.32 million, a P/E ratio of -3.56 and a beta of -0.01. The stock's 50 day moving average price is $12.35 and its 200 day moving average price is $10.74.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of KALV. Aquatic Capital Management LLC acquired a new position in KalVista Pharmaceuticals during the fourth quarter worth approximately $44,000. Earned Wealth Advisors LLC acquired a new position in KalVista Pharmaceuticals during the first quarter worth approximately $44,000. GAMMA Investing LLC increased its position in KalVista Pharmaceuticals by 567.3% during the first quarter. GAMMA Investing LLC now owns 4,431 shares of the specialty pharmaceutical company's stock worth $51,000 after purchasing an additional 3,767 shares during the last quarter. CWM LLC increased its position in shares of KalVista Pharmaceuticals by 12,636.1% in the first quarter. CWM LLC now owns 4,585 shares of the specialty pharmaceutical company's stock worth $53,000 after acquiring an additional 4,549 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its position in shares of KalVista Pharmaceuticals by 666.9% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company's stock worth $54,000 after acquiring an additional 5,502 shares in the last quarter.

Insider Activity

In related news, CEO Benjamin L. Palleiko sold 7,169 shares of the company's stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $14.50, for a total transaction of $103,950.50. Following the completion of the transaction, the chief executive officer now owns 315,074 shares of the company's stock, valued at approximately $4,568,573. This represents a 2.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Venrock Healthcare Capital Par purchased 25,000 shares of the company's stock in a transaction that occurred on Wednesday, April 9th. The shares were bought at an average cost of $9.42 per share, with a total value of $235,500.00. Following the transaction, the insider now directly owns 5,303,985 shares of the company's stock, valued at $49,963,538.70. The trade was a 0.47% increase in their position. The disclosure for this purchase can be found here. Insiders sold a total of 15,899 shares of company stock valued at $206,176 over the last 90 days. Insiders own 10.50% of the company's stock.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).